ELITE PHARMACEUTICALS INC | 8-K: Current report
ELITE PHARMACEUTICALS INC | 8-K: Current report
ELITE PHARMACEUTICALS INC | 8-K: Current report
ELITE PHARMACEUTICALS INC | 4: Statement of changes in beneficial ownership of securities-Officer Hakim Nasrat A
ELITE PHARMACEUTICALS INC | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Hakim Nasrat A
ELITE PHARMACEUTICALS INC | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
ELITE PHARMACEUTICALS INC | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
ELITE PHARMACEUTICALS INC | UPLOAD: Others
ELITE PHARMACEUTICALS INC | CORRESP: CORRESP
ELITE PHARMACEUTICALS INC | 8-K: Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
ELITE PHARMACEUTICALS INC | 10-Q: Quarterly report
ELITE PHARMACEUTICALS INC | UPLOAD: Others
ELITE PHARMACEUTICALS INC | 4: Statement of changes in beneficial ownership of securities-Officer Hakim Nasrat A
ELITE PHARMACEUTICALS INC | 8-K: Current report
ELITE PHARMACEUTICALS INC | 8-K: Current report
ELITE PHARMACEUTICALS INC | 4: Statement of changes in beneficial ownership of securities-Director WHITNELL JEFFREY A
ELITE PHARMACEUTICALS INC | 4: Statement of changes in beneficial ownership of securities-Director Caskey Davis S
ELITE PHARMACEUTICALS INC | 4: Statement of changes in beneficial ownership of securities-Director Dash Barry H
ELITE PHARMACEUTICALS INC | 8-K: Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
ELITE PHARMACEUTICALS INC: Q2 2024 Earnings Report
No Data